Selinexor: A first-in-class SINE compound for treatment of relapsed refractory multiple myeloma

Shambavi Richard, Joshua Richter, Sundar Jagannath

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

The progression of multiple myeloma is accompanied by complex cytogenetic and epigenetic alterations that include mutation or functional inactivation of tumor suppressor proteins and overexpression of oncoproteins. Patients whose myeloma is refractory to the three major classes of drugs including immunomodulatory agents, proteasome inhibitors and anti-CD38 monoclonal antibodies have a very poor prognosis. Drugs with novel mechanisms of action that can bypass resistance mechanisms are sorely needed for this group of patients. Selinexor represents a novel, oral agent with an innovative mechanism of action that offers a significant therapeutic advance in this group of heavily treated patients. Moreover, this novel mechanism may provide additional options for patients with less refractory disease.

Original languageEnglish
Pages (from-to)1331-1350
Number of pages20
JournalFuture Oncology
Volume16
Issue number19
DOIs
StatePublished - Jul 2020

Keywords

  • SINE
  • XPO1
  • exportin 1
  • karyopherin
  • multiple myeloma
  • refractory
  • relapsed
  • selective inhibitor of nuclear export
  • selinexor

Fingerprint

Dive into the research topics of 'Selinexor: A first-in-class SINE compound for treatment of relapsed refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this